All In Biotech

Drug Trial Radar · NCT07629336

SAR447971 First-in-human Study

A Randomized, First-in-human, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Oral Doses (SAD20411) and Multiple Ascending Doses (MAD20412) of SAR447971 With Food Effect Evaluation in Healthy Participants and of Multiple Ascending Doses (MAD24339) of SAR447971 in Patients With Hidradenitis Suppurativa

Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 122 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

122

Planned (sponsor's estimate)

Start

May 26, 2026

Primary completion

Apr 17, 2028

Study completion Apr 17, 2028

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
Collaborators
Kymera Therapeutics, Inc.
First posted
Jun 5, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

SAD20411 is a single-center, first-in-human, double-blind, randomized, placebo-controlled, sequential single ascending dose study in healthy male and/or female participants with a pilot food effect investigation. MAD20412 is a single-center, double-blind, randomized, placebo-controlled, sequential multiple ascending dose study in healthy male and/or female participants. MAD24339 is an open-label, sequential multiple ascending dose study in hidradenitis suppurativa (HS) male and/or female participants. Number of participants The total expected number of healthy participants is approximately 102 and the total number of HS participants is expected to be approximately 20. * SAD20411 will enroll up to 54 participants * MAD20412 will enroll up to 48 participants * MAD24339 will enroll up to 20 participants Duration of study The anticipated study duration per participant is up to approximately 10 weeks in SAD20411 and MAD20412, and up to approximately 12 weeks in MAD24339.

Conditions

  • Hidradenitis
  • Healthy Volunteers

Interventions

  • SAR447971Drug

    Pharmaceutical form: Tablet Route of administration: Oral

  • PlaceboDrug

    Pharmaceutical form: Tablet Route of administration: Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. SAD20411: Incidence of treatment emergent adverse events (TEAEs)Time frame: Day 1 to Day 15
  2. SAD20411: Incidence of clinically significant abnormalities in clinical laboratory evaluations (hematology, biochemistry, coagulation, urinalysis)Time frame: Day 1 to Day 15
  3. SAD20411: Incidence of clinically significant abnormalities in vital signsTime frame: Day 1 to Day 15
  4. SAD20411: Incidence of clinically significant abnormalities in ECG (heart rate, PR, QRS, QT, QTcF)Time frame: Day 1 to Day 15
  5. MAD20412: Incidence of treatment emergent adverse events (TEAEs)Time frame: Day 1 to Day 29
  6. MAD20412: Incidence of clinically significant abnormalities in clinical laboratory evaluations (hematology, biochemistry, coagulation, urinalysis)Time frame: Day 1 to Day 29
  7. MAD20412: Incidence of clinically significant abnormalities in vital signsTime frame: Day 1 to Day 29
  8. MAD20412: Incidence of clinically significant abnormalities in ECG (heart rate, PR, QRS, QT, QTcF)Time frame: Day 1 to Day 29
  9. MAD24339: Incidence of treatment emergent adverse events (TEAEs)Time frame: Day 1 to Day 42
  10. MAD24339: Incidence of clinically significant abnormalities in clinical laboratory evaluations (hematology, biochemistry, coagulation, urinalysis)Time frame: Day 1 to Day 42
  11. MAD24339: Incidence of clinically significant abnormalities in vital signsTime frame: Day 1 to Day 42
  12. MAD24339: Incidence of clinically significant abnormalities in ECG (heart rate, PR, QRS, QT, QTcF)Time frame: Day 1 to Day 42

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Investigational Site Number: 5280001

    Leiden, Netherlands · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.